{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:41:11Z","timestamp":1783698071954,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021110","name":"Irish MPS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101127","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T13:18:41Z","timestamp":1697807921000},"page":"101127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Stuart","family":"Ellison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne F.E.","family":"Gleitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Holley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Bigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101127_bib1","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2023.101127_bib2","series-title":"GeneReviews(\u00ae)","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"1993"},{"key":"10.1016\/j.omtm.2023.101127_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological Lysosomal Storage Disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2023.101127_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2023.101127_bib5","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2023.101127_bib6","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib7","doi-asserted-by":"crossref","first-page":"965089","DOI":"10.3389\/fmolb.2022.965089","article-title":"Delivering gene therapy for mucopolysaccharide diseases","volume":"9","author":"Wood","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtm.2023.101127_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","article-title":"The role of antibodies in enzyme treatments and therapeutic strategies","volume":"29","author":"Bigger","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.omtm.2023.101127_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","article-title":"Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"2","author":"Hobbs","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2023.101127_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13023-020-01644-w","article-title":"Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT)","volume":"16","author":"Guffon","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.101127_bib11","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/ijms23094854","article-title":"Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?","volume":"23","author":"Horgan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2023.101127_bib12","doi-asserted-by":"crossref","first-page":"e8730","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2023.101127_bib13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib14","doi-asserted-by":"crossref","first-page":"e86696","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2023.101127_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-005-0069-y","article-title":"Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses","volume":"28","author":"Tomatsu","year":"2005","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2023.101127_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jnc.14632","article-title":"The role of innate immunity in mucopolysaccharide diseases","volume":"148","author":"Parker","year":"2019","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtm.2023.101127_bib17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/ijms23041999","article-title":"Innate Immunity in Mucopolysaccharide Diseases","volume":"23","author":"Mandolfo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2023.101127_bib18","doi-asserted-by":"crossref","first-page":"e11185","DOI":"10.15252\/emmm.201911185","article-title":"Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA","volume":"12","author":"Parker","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2023.101127_bib19","article-title":"Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease","author":"Mandolfo","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2023.101127_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2023.101127_bib22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/hum.2022.141","article-title":"Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of Ex\u00a0Vivo Lentiviral Vector-Transduced Hematopoietic Stem and Progenitor Cells","volume":"33","author":"Smith","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib23","series-title":"FDA clinical hold of phase 3 CALD trial","year":"2021"},{"key":"10.1016\/j.omtm.2023.101127_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","article-title":"Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy","volume":"507","author":"Cartier","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.omtm.2023.101127_bib25","doi-asserted-by":"crossref","first-page":"107171","DOI":"10.1016\/j.ymgme.2022.107171","article-title":"Sustained biochemical engraftment and early clinical outcomes following ex-vivo autologous stem cell gene therapy for mucopolysaccharidosis type IIIA","volume":"138","author":"Jones","year":"2023","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2023.101127_bib26","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.101127_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/brain\/awx311","article-title":"Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy","volume":"141","author":"Holley","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2023.101127_bib28","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.101127_bib29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.oret.2021.09.008","article-title":"Alphabet Soup: Clinical Pearls for the Retina Specialist-Ocular Toxicity of Advanced Antineoplastic Agents in Systemic Cancer Care","volume":"5","author":"Villegas","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.omtm.2023.101127_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(83)34600-5","article-title":"Ocular toxicity of antineoplastic agents","volume":"90","author":"Fraunfelder","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2023.101127_bib31","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.3748\/wjg.v23.i22.4039","article-title":"Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis","volume":"23","author":"Matusiewicz","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omtm.2023.101127_bib32","doi-asserted-by":"crossref","first-page":"14314","DOI":"10.18632\/oncotarget.15177","article-title":"Neutralization of interleukin-9 ameliorates symptoms of allergic rhinitis by reducing Th2, Th9, and Th17 responses and increasing the Treg response in a murine model","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2023.101127_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3389\/fimmu.2018.01139","article-title":"A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease","volume":"9","author":"Vyas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.101127_bib34","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.4373","article-title":"Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells","volume":"23","author":"Rauber","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101127_bib35","doi-asserted-by":"crossref","first-page":"120180","DOI":"10.1016\/j.lfs.2021.120180","article-title":"Interleukin-9 attenuates inflammatory response and hepatocyte apoptosis in alcoholic liver injury","volume":"288","author":"Meng","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.omtm.2023.101127_bib36","doi-asserted-by":"crossref","first-page":"843242","DOI":"10.3389\/fimmu.2022.843242","article-title":"The Role of Metabolic Dysfunction in T-Cell Exhaustion During Chronic Viral Infection","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.101127_bib37","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/microorganisms9122460","article-title":"T-Cell Exhaustion in Mycobacterium tuberculosis and Nontuberculous Mycobacteria Infection: Pathophysiology and Therapeutic Perspectives","volume":"9","author":"Lombardi","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.omtm.2023.101127_bib38","doi-asserted-by":"crossref","first-page":"2035117","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T\u00a0cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.omtm.2023.101127_bib39","doi-asserted-by":"crossref","first-page":"100130","DOI":"10.1016\/j.jtauto.2021.100130","article-title":"Regulatory T\u00a0cell function in autoimmune disease","volume":"4","author":"Rajendeeran","year":"2021","journal-title":"J.\u00a0Transl. Autoimmun."},{"key":"10.1016\/j.omtm.2023.101127_bib40","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/mt.2012.82","article-title":"Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice","volume":"20","author":"Langford-Smith","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib41","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2023.101127_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ymthe.2005.01.022","article-title":"Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells","volume":"12","author":"Siapati","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101127_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jviromet.2008.11.021","article-title":"Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection","volume":"157","author":"Kuroda","year":"2009","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.omtm.2023.101127_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/bc900382q","article-title":"Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase","volume":"21","author":"Lu","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.omtm.2023.101127_bib45","doi-asserted-by":"crossref","first-page":"37515","DOI":"10.1074\/jbc.M111.287474","article-title":"Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking alpha-l-iduronidase","volume":"286","author":"Holley","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.101127_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtm.2019.04.001","article-title":"Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex\u00a0Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA","volume":"13","author":"Ellison","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:20:32Z","timestamp":1762615232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"alternative-id":["S2329050123001663"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101127","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101127"}}